Collectively, our data confirmed that the activation of autophagy, which occurs as a consequence of Tam treatment, contributes to Tam resistance of ER+ breast cancer cells by relocating inside the lysosomal lumen the protective factors capable of restraining the drug-induced lysosomal damage. Here, ESR1 is linked to breast carcinoma.